NASDAQ · ASND
Healthcare · Biotechnology
$228.03
Up+$0.16 (+0.07%)
Updated Oct 6, 2026, 4:12 AM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ASND
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ASND closed at $228.03 after 20 trading sessions, down 15.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $229.66 | $230.732 | $226.84 | $228.03 | 783.23K |
| Oct 2, 2026 | $227.63 | $229.02 | $225.20 | $227.87 | 641.44K |
| Oct 1, 2026 | $228.03 | $229.88 | $226.00 | $227.31 | 805.98K |
| Sep 30, 2026 | $227.97 | $230.97 | $226.18 | $227.83 | 926.23K |
| Sep 29, 2026 | $227.42 | $229.89 | $223.70 | $228.07 | 741.87K |
| Sep 28, 2026 | $226.00 | $231.14 | $224.805 | $230.05 | 747.55K |
| Sep 25, 2026 | $230.13 | $230.43 | $224.2635 | $225.60 | 419.97K |
| Sep 24, 2026 | $223.00 | $231.13 | $220.2302 | $230.70 | 1.17M |
| Sep 23, 2026 | $236.83 | $237.98 | $220.595 | $223.13 | 1.22M |
| Sep 22, 2026 | $239.09 | $240.69 | $234.67 | $237.57 | 548.32K |
| Sep 21, 2026 | $238.66 | $241.505 | $237.00 | $237.59 | 822.99K |
| Sep 18, 2026 | $238.15 | $243.68 | $236.02 | $236.72 | 1.56M |
| Sep 17, 2026 | $249.23 | $249.23 | $237.13 | $239.04 | 1.1M |
| Sep 16, 2026 | $239.70 | $249.005 | $237.225 | $247.69 | 1.26M |
| Sep 15, 2026 | $257.17 | $257.53 | $228.56 | $239.77 | 2.96M |
| Sep 14, 2026 | $265.00 | $265.50 | $260.00 | $264.92 | 417.85K |
| Sep 11, 2026 | $263.34 | $266.34 | $259.48 | $263.515 | 443.61K |
| Sep 10, 2026 | $260.00 | $262.17 | $258.01 | $261.23 | 505.04K |
| Sep 9, 2026 | $270.89 | $272.3703 | $260.75 | $260.81 | 497.43K |
| Sep 8, 2026 | $263.41 | $272.4665 | $262.32 | $270.09 | 653.37K |
The latest Smart Investors Daily articles mentioning ASND.
Company
Market Activity
Research & News
ASND research
Company profile and research snapshot.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Raymond James | Outperform | — |
| Sep 2, 2026 | Oppenheimer | Outperform | — |
| Sep 1, 2026 | Wedbush | Outperform | — |
| Sep 1, 2026 | Morgan Stanley | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 30, 2026
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization of
Yahoo · Sep 21, 2026
On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]
Yahoo · Sep 19, 2026
Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...
Yahoo · Sep 17, 2026
Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ASND.
